Trials / Terminated
TerminatedNCT01034410
A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
An Open-label Randomized Controlled Phase II Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Antisoma Research · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label randomized controlled phase II study of AS1411 combined with Cytarabine in the treatment of patients with primary refractory or relapsed acute myeloid leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AS1411 | AS1411 40mg/kg/day or AS1411 80mg/kg/day |
| DRUG | Cytarabine | Cytarabine 2g/m2 bid Days 4-7 |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2009-12-17
- Last updated
- 2011-02-02
Locations
14 sites across 4 countries: United States, Australia, New Zealand, Taiwan
Source: ClinicalTrials.gov record NCT01034410. Inclusion in this directory is not an endorsement.